Aetna settles with patient who sued for coverage denial

A little over a year ago, California’s insurance commissioner began investigating Aetna for possibly denying care coverage without reviewing the records of a patient who’d filed a lawsuit. Now the company has agreed to an out-of-court settlement.

The insurance giant’s trouble in this case started in 2016, when a 23-year-old man sued over a denial of coverage for infusion treatments he needed for a rare immune disorder.

Next, in February 2018, a former medical director of Aetna said during a videotaped deposition that he had not personally perused the patient’s medical records before deciding whether to approve or deny these insurance claims. Instead, he said, he relied on recommendations from nurses—and added that this practice was not unusual at Aetna.  

It was this latter admission, made under oath, that spurred the investigation.

CNN covered the settlement April 26, noting its terms were not disclosed and that Aetna is now a part of CVS.

“Given the importance of how benefits determinations are made by Aetna and other companies, I would hope we could get more transparency of their procedures,” a medical-ethics professor at NYU told CNN reporter Wayne Drash. “I thought it might come out of this case, but sadly it doesn’t appear so.”

The implication was that a desire to avoid full transparency may explain the company’s quiet settlement of a suit the grounds for which Aetna initially denied quite vehemently.

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.